SF-1126

CAS No. 936487-67-1

SF-1126( SF 1126 | SF1126 )

Catalog No. M16703 CAS No. 936487-67-1

SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 732 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
5MG 732 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    SF-1126
  • Note
    Research use only, not for human use.
  • Brief Description
    SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.
  • Description
    SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins; blocks expression levels of c-Myc in HCC cells, inhibits proliferation, cell cycle, apoptosis, PI3K/AKT/mTOR and Ras/Raf/MAPK pathway; shows significant antitumor activity in vivo.Liver Cancer Phase 1 Clinical.
  • In Vitro
    SF1126 (0-6 μM; 48 hours) inhibits Hep3B, HepG2, SK-Hep1, and Huh7 cells proliferation with IC50s of 5.05, 6.89, 3.14, and 2.14 μM, respectively.SF1126 (1-10 μM; 24 hours) results in cell-cycle arrest with a proportional increase in G0-G1 and a decrease in the number of cells in the S-phase in Hep 3B, Hep G2, SK-Hep1, and Huh7 cells.SF1126 (0.5-2.5 μM; pre-30 minutes) and sorafenib suggests that combined treatment of SF1126 and sorafenib blocks multiple key enzymes in PI3K/AKT/mTOR and Ras/Raf/MAPK pathway. Cell Viability Assay Cell Line:Hep3B, HepG2, SK-Hep1, and Huh7 cells Concentration:0 μM; 1 μM; 2 μM; 3 μM; 4 μM; 5 μM; 6 μM Incubation Time:48 hours Result:Resulted in an increased inhibition of HCC proliferation. Cell Cycle Analysis Cell Line:Hep3B, HepG2, SK-Hep1, and Huh7 cells Concentration:1 μM; 5 μM; 10 μM Incubation Time:24 hours Result:Induced cell-cycle arrest.Western Blot Analysis Cell Line:Hep3B, HepG2, SK-Hep1, and Huh7 cells Concentration:0.5 μM and 2.5 μM Incubation Time:Pre-30 mins Result:Suppressed phosphorylation of AKT, p70S6K, 4EBP1, and ERK in all the cell lines together with sorafenib.
  • In Vivo
    ——
  • Synonyms
    SF 1126 | SF1126
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3K
  • Research Area
    Cancer
  • Indication
    Liver Cancer

Chemical Information

  • CAS Number
    936487-67-1
  • Formula Weight
    852.84
  • Molecular Formula
    C39H48N8O14
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C([O-])[C@H](CO)NC([C@H](CC(O)=O)NC(CNC([C@H](CCCNC(N)=N)NC(CCC(OC[N+]1(C2=CC(C3=C(O2)C(C4=CC=CC=C4)=CC=C3)=O)CCOCC1)=O)=O)=O)=O)=O
  • Chemical Name
    (4-oxo-4-((4-(4-oxo-8-phenyl-4H-chromen-2-yl)morpholino-4-ium)methoxy)butanoyl)-L-arginylglycyl-L-aspartyl-L-serinate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Garlich JR, et al. Cancer Res. 2008 Jan 1;68(1):206-15. 2. Dittmann A, et al. ACS Chem Biol. 2014 Feb 21;9(2):495-502. 3. Erdreich-Epstein A, et al. Oncotarget. 2016 Nov 16. doi: 10.18632/oncotarget.13386.
molnova catalog
related products
  • AZD8186

    AZD8186 is a potent, isoform-specific PI3Kβ inhibitor with IC50 of 4 nM, also inhibits PI3Kδ (IC50=12 nM) with selectivity over PI3Kα (IC50=35 nM) and PI3Kγ (IC50=675 nM).

  • PQR309

    PQR309 (Bimiralisib) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50 of 33, 451, 661, 708 and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively.

  • Parsaclisib

    Parsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP).